REVMATOID ARTRIT TERAPIYASINING ZAMONAVIY TAMOYILLARI: EULAR 2025  VA ACR 2021 TAVSIYALARINING QIYOSIY TAHLILI

Sapayeva Sharofat; Islomov Inomjon; Xudoyberdiyev Muzaffar; Pulatova Ma`mura

Authors

Sapayeva Sharofat
Islomov Inomjon
Xudoyberdiyev Muzaffar Terapevt
Pulatova Ma`mura Urganch davlat tibbiyot instituti, terapiya (ichki kasalliklar) yo`nalishi 2-kurs klinik ordinatori.

Keywords:

revmatoid artrit, Treat-to-Target, metotreksat, csDMARD, bDMARD, tsDMARD, JAK-ingibitorlari, EULAR, ACR.

Abstract

Revmatoid artrit (RA) – surunkali tizimli autoimmun yalig`lanish bilan kechadigan, bo`g`imlarning progressiv, destruksiyasi, funksional cheklanish va tizimli asoratlar bilan kechadigan revmatologik kasalliklardan biridir. Zamonaviy RA terapiyasining asosiy maqsadi
kasallik faolligini erta nazorat qilish, klinik remissiya yoki past kasallik faolligiga erishish va strukturaviy bo`g`im shikastlanishining oldini olishdan iborat. Ushbu tezisda EULARning 2025 yilgi yangilangan tavsiyalari va ACRning 2021-yilgi klinik guideline hujjati qiyosiy tahlil qilindi.

Downloads

Download data is not yet available.

References

1. Solmen JS, Edwards CJ, Konzett V, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update. Ann Rheum Dis. 2026;85(6):991-1009. doi: 10.1016/j.ard.2026.01.023.

2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2021;73(7):1108 1123. doi: 10.1002/art.41752.

3. Sebbag E, Lauper K, Monila-Collada J, et al. 2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer. Ann Rheum Dis. 2024. doi:10.1136/ard-2024-225982.

4. Лила А.М., ред. Ревматология. Оксфордский справочник. Москва: ГЭОТАР-Медиа; 2025.